advice

Tariffs and Import-Duty Risk on Overseas Medical Devices: What Supply-Chain Leaders Need to Know

April 30, 2026· 6 min read· AI-generated

Tariffs and Import-Duty Risk on Overseas Medical Devices: What Supply-Chain Leaders Need to Know

How shifting trade policy can quietly add six figures to a device budget—and what procurement teams can do about it before the invoice arrives.

Why this matters

Picture this: a regional hospital system finalises a three-year contract for ultrasound probes manufactured in China. The per-unit price is negotiated, the clinical evaluation is complete, and the capital budget is approved. Then, eight weeks before the first shipment clears customs, the U.S. Trade Representative expands a Section 301 tariff list, and the applicable rate on that HTS subheading jumps from 7.5% to 25%. The manufacturer's quoted price didn't include that exposure. Neither did the hospital's purchase order. The result is an unplanned cost that falls somewhere between the distributor and the health system's accounts payable team, and nobody is happy.

That scenario is not hypothetical in structure. Section 301 tariffs on Chinese-origin goods, first imposed in 2018 and revised multiple times since, have touched a wide range of HTS Chapter 90 product categories—the chapter that covers most medical, surgical, dental, and veterinary instruments and apparatus. Some categories saw temporary exclusions during the COVID-19 public health emergency; others did not, and exclusion lists have changed repeatedly. Supply-chain leaders who assumed a tariff rate was fixed at the time of contract signature have repeatedly found that assumption doesn't survive contact with a revised Federal Register notice (S1).

The deeper issue is that tariff risk sits at the intersection of trade law, customs classification, and contract language—three specialties that rarely share the same department in a healthcare organisation. Clinical engineering focuses on device performance; finance focuses on capital authorisation; legal focuses on warranty and liability. Nobody owns customs exposure until a customs broker calls with a detention notice or an unexpected duty bill. The goal of this article is to explain the moving parts clearly enough that procurement teams can start asking the right questions before a contract is signed.

The decisions that shape the outcome

How the device is classified under the Harmonized Tariff Schedule

Every imported product enters customs under a 10-digit HTS code, and the duty rate—and whether a Section 301 or antidumping tariff applies—flows from that classification. Two physically similar devices can legitimately land in different HTS subheadings depending on their primary function, and that classification difference can mean the gap between duty-free entry and a 25% ad valorem rate. Procurement teams should never accept an HTS code from a foreign supplier without independent verification. The U.S. International Trade Commission's online HTS database is publicly accessible (S2), and for high-value or recurring purchases, requesting a binding ruling from U.S. Customs and Border Protection gives you a classification that CBP itself is committed to honour.

Where the product is actually manufactured, not just sold

Country of origin rules are frequently misunderstood. A device may be marketed by a European distributor, invoiced from a Singapore entity, and still be considered Chinese-origin for tariff purposes if substantial transformation occurred in China. CBP applies a "substantial transformation" test: the country where the product last underwent a fundamental change in character or use is the country of origin (S3). For combination devices—say, a capital imaging platform with Chinese-made detector arrays assembled in South Korea—the origin analysis can be genuinely ambiguous. If the supplier can't produce a detailed bill of materials and a written country-of-origin determination, that's a due-diligence gap worth resolving before contract execution.

How the contract allocates tariff risk

Most standard vendor agreements are silent on what happens if tariff rates change after signature. A delivery-duty-unpaid (DDU) or ex-works pricing structure leaves the import cost entirely with the buyer. Even a delivered-duty-paid (DDP) contract only protects you if the seller has explicitly assumed the risk of rate changes, not just the currently-known rate at the time of signing. Procurement and legal teams should consider adding a tariff-change clause that specifies a mechanism—price renegotiation, shared burden, or early termination right—when a duty rate shifts by more than a defined threshold. This is a negotiable point with most international suppliers, and it's far easier to negotiate before a PO is issued than after a shipment is held at port.

Whether free-trade agreements or duty-mitigation programs apply

Not all imports from tariff-exposed countries face the same exposure. The United States-Mexico-Canada Agreement (USMCA) provides preferential—often zero—duty rates for qualifying goods of North American origin, and a number of medical device manufacturers have shifted or expanded North American assembly operations specifically to take advantage of this (S1). For non-FTA countries, duty drawback programs allow importers to recover up to 99% of duties paid on goods that are subsequently exported or destroyed under CBP supervision—a mechanism relevant to distributors and to health systems that export devices for humanitarian programs. Foreign-trade zones (FTZs) near major ports offer another avenue: goods can be admitted to an FTZ, undergo value-added activity, and in some cases be reclassified or re-exported with a different duty outcome. These aren't exotic arrangements; CBP publishes an active list of FTZ operators (S3).

Common mistakes

The most common error is treating tariff costs as a supplier problem rather than a shared exposure. Procurement officers frequently assume that because a vendor quotes a landed price, the vendor has accounted for tariff changes. In practice, many foreign suppliers quote at the currently applicable rate and include language—buried in exhibit C of their commercial terms—that passes through any subsequent duty increases. A health system that signed a large capital contract in early 2018 and received shipment post-July 2018 after the first Section 301 list took effect may have faced exactly this situation, depending on their contract language.

A second mistake is relying on the supplier's HTS classification without question. Suppliers sometimes apply the lowest-duty classification that is defensible (or occasionally, classifications that are not defensible). If CBP audits an entry and reclassifies a device into a higher-duty category, the importer of record—not the foreign manufacturer—is liable for back duties, interest, and potential penalties. The importer of record is typically the U.S. buyer or their broker, not the overseas seller.

Third, organisations frequently fail to re-evaluate tariff exposure when they renew or extend existing contracts. A device that was manufactured in Taiwan in 2019 may now be sourced from a Chinese contract manufacturer under the same brand name. Without asking explicitly about manufacturing location at each contract renewal, supply-chain teams can inherit origin risk they didn't have before.

Fourth, duty-mitigation tools like first-sale valuation are underused. When a foreign manufacturer sells to a middleman distributor who then sells to a U.S. importer, CBP generally allows the dutiable value to be calculated on the earlier factory-to-distributor price rather than the distributor-to-importer price. For devices with significant distribution mark-ups, this can produce meaningful duty savings—but the documentation requirements are strict, and the program must be set up proactively, not retroactively.

A practical workflow

Verify HTS classification independently before contracting. Confirm the 10-digit code using the USITC database and consider a CBP binding ruling for any device category exceeding $250,000 in annual import value.
Obtain a written country-of-origin determination from the supplier. Request the bill of materials and manufacturing location for major components; don't accept "country of origin: [country]" on a datasheet as a substitute for a reasoned analysis.
Add a tariff-change clause to the supply agreement. Define the trigger (e.g., any duty rate increase above 5 percentage points) and the remedy (cost-share negotiation, price adjustment, or exit right).
Run a duty-mitigation analysis before the first shipment. Engage a licensed customs broker to evaluate FTZ eligibility, first-sale valuation, and drawback opportunities specific to your product mix.
Set a calendar reminder to re-evaluate at every contract renewal. Ask the supplier explicitly whether manufacturing location or sub-supplier origin has changed since the previous contract term.
Monitor USTR and Federal Register notices on an ongoing basis. Section 301 lists and exclusion decisions are published in the Federal Register with comment periods; early awareness allows you to respond before a shipment is in transit.

Sources

MedSource publishes neutral guidance. We do not accept payment from vendors to influence the content of articles. AI-generated articles are reviewed for factual accuracy but cited sources should be the primary reference for procurement decisions.